Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer

被引：0
|
作者：
Muhammad Wasif Saif
K. I. Syrigos
S. Hotchkiss
J. Shanley
J. Grasso
T. M. Ferencz
K. Syrigos
M. M. Shah
机构：
[1] Yale University School of Medicine,Section of Medical Oncology
[2] Athens School of Medicine,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2009年 / 65卷
关键词：
Cetuximab (Erbitux); Panitumumab; Epidermal growth factor receptor (EGFR); Colorectal cancer; Hypersensitivity reaction; Infusion reaction; Desensitization;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：107 / 112
页数：5
相关论文
共 50 条
  • [41] Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer
    Bardelli, Alberto
    Bianchi, Andrea Sartore
    Di Nicolantonio, Federica
    Nichelatti, Michele
    Molinari, Francesca
    De Dosso, Sara
    Saletti, Piercarlo
    Martini, Miriam
    Sarnataro, Carolina
    Pozzi, Federico
    Mazzucchelli, Luca
    Lamba, Simone
    Veronese, Silvio
    Frattini, Milo
    Siena, Salvatore
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [42] Panitumumab - In the treatment of metastatic colorectal cancer
    Hoy, Sheridan M.
    Wagstaff, Antona J.
    DRUGS, 2006, 66 (15) : 2005 - 2014
  • [43] KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal Cancer
    Jimeno, Antonio
    Messersmith, Wells A.
    Hirsch, Fred R.
    Franklin, Wilbur A.
    Eckhardt, S. Gail
    CANCER JOURNAL, 2009, 15 (02): : 110 - 113
  • [44] ASPECCT: panitumumab versus cetuximab for colorectal cancer Reply
    Price, Timothy J.
    Peeters, Marc
    Ruff, Paul
    Murugappan, Swaminathan
    Sidhu, Roger
    LANCET ONCOLOGY, 2014, 15 (08): : E303 - E303
  • [45] Metastatic colorectal cancer: treatment with panitumumab
    Silvinato, Antonio
    Pedreira, Isabela da Silveira
    Bueno dos Reis, Joao Conrado
    Zetula Marcondes, Joao Guilherme
    Bernardo, Wanderley M.
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2018, 64 (07): : 568 - 574
  • [46] Circulating tumor cells as predictive marker in panitumumab after progression of cetuximab in Japanese patients with KRAS wild-type metastatic colorectal cancer
    Ohhara, Yoshihito
    Matsusaka, Satoshi
    Shinozaki, Eiji
    Suenaga, Mitsukuni
    Mizunuma, Nobuyuki
    Hatake, Kiyohiko
    Yamaguchi, Toshiharu
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [47] Panitumumab for the treatment of metastatic colorectal cancer
    Pinguet, Frederic
    EJHP PRACTICE, 2009, 15 (06): : 66 - 69
  • [48] Spotlight on Panitumumab in Metastatic Colorectal Cancer
    Keating, Gillian M.
    BIODRUGS, 2010, 24 (04) : 275 - 278
  • [49] Spotlight on Panitumumab in Metastatic Colorectal Cancer
    Gillian M. Keating
    BioDrugs, 2010, 24 : 275 - 278
  • [50] BRAF V600E confers resistance to cetuximab or panitumumab metastatic colorectal cancer
    Di Nicolantonio, F.
    Martini, M.
    Molinari, F.
    Bianchi, A. Sartore
    Arena, S.
    Saletti, P.
    Mazzucchelli, L.
    Frattini, M.
    Siena, S.
    Bardelli, A.
    EJC SUPPLEMENTS, 2008, 6 (12): : 81 - 81
12345